Recent politicization of the COVID-19 vaccine development and approval process has led to a concerning loss of confidence in vital governmental institutions. Each day that goes by, the picture seems to grow darker. Politicians criticize scientists without cause.
The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
Another public health crisis looms in the wake of the COVID-19 pandemic.
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.
For nearly 200 years, USP’s public standards have served to establish a common foundation upon which the quality of medicines can be evaluated, building trust in the healthcare system and enabling innovation to thrive. During that time, medicine has evolved tremendously.
I was pleased to address the American Association of Pharmaceutical Scientists (AAPS) on May 12 during a webinar focused on the impact of the COVID-19 pandemic on the supply of quality medicines.